Thalassemia Treatment Market, Size, Share, Opportunities and Forecast, 2020-2027

SKU: DPH130 | Last Updated On: Sep 09 2020 | No. of Pages: 190 | Available Formats

> Global Thalassemia Treatment Market Expected to reach a high CAGR of 10.5% By 2027: DataM Intelligence

Global Thalassemia Treatment Market is segmented By Disease Type (Alpha Thalassemia, Beta Thalassemia), By Treatment Type (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Gene Therapy, Surgery), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027

 

Market Overview

The Global Thalassemia Treatment Market is expected to grow at a CAGR of 10.5% during the forecasting period (2020-2027).

Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin, the protein in red blood cells that carries oxygen. This causes a shortage of red blood cells and low levels of oxygen in the bloodstream, leading to a variety of health problems. Signs and symptoms vary but may include mild to severe anemia, paleness, fatigue, yellow discoloration of skin, and bone problems. When there are not enough healthy red blood cells, there is also not enough oxygen delivered to all the other cells of the body, which may cause a person to feel tired, weak or short of breath. This is a condition called anemia. People with thalassemia may have mild or severe anemia. Severe anemia can damage organs and lead to death.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The thalassemia treatment market growth is driven by several factors, such as an increase in the prevalence of thalassemia, a rise in global awareness and, increasing investment in research and development.

Inherited hemoglobin disorders (sickle-cell disorders and thalassemias) were initially characteristic of the tropics and subtropics but are now common worldwide due to migration. According to the World Health Organization (WHO), thalassemia is sufficiently common in 71% of countries of the world and among 89% of births. At least 5.2% of the world’s population and over 7% of pregnant women carry a significant variant. Moreover, at least 20% of the world population carries α+ thalassemia. Around 1.1% of couples worldwide are at risk of having children with thalassemia, and 2.7 per 1000 conceptions are affected. Annually there are over 56,000 births that have a major thalassemia, including at least 30,000 who need regular transfusions to survive and 5,500 who die perinatally due to α thalassemia major. Increasing cases of thalassemia require a universal cure for the treatment of the disease, hence boosting the market growth globally.

An increase in awareness about thalassemia is very important for the prevention of the disease. Many organizations are working towards this cause by initiating awareness campaigns. Governments of countries are also supporting the cause by investing in these programs. For instance, International Thalassaemia Day is celebrated on May 8 every year to raise awareness amongst people concerned with decision and policymaking, health care professionals, patients, and their families and community at large about thalassemia. A vast majority of the population is mostly unaware of the disease and especially those areas where it is more prevalent such as Asia Pacific and Mediterranean. Center for Disease Control and Prevention (CDC) funds one project that monitors blood safety in people with blood disorders.  This project is called “Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies.” Georgia State University, the University of Florida, and the University of California at San Francisco Benioff Children’s Hospital Oakland have been awarded funding to look at transfusion-related complications in people with hemoglobin disorders (sickle cell disease and thalassemia) and develop approaches for reducing these complications. Besides, CDC funds the Association of Public Health Laboratories to provide public health technical assistance with screening (a test to look for a disease before it is noticeable) activities, including needs assessments for laboratories, as well as education for patients, caregivers, and healthcare workers on hemoglobinopathy screening programs.

Market Segmentation

By disease type, the global thalassemia treatment market is segmented as alpha-thalassemia and beta-thalassemia. Alpha thalassemia is expected to hold the largest market share over the period of forecast (2020-2027) owning to higher prevalence of the disease globally. According to National Organization for Rare Disorders, alpha thalassemia occurs in 4-20 individuals per every 1,000 births. Alpha thalassemia is found in most populations worldwide but is most common in the Middle East, Southeast Asia, and certain Mediterranean countries. Doctors in Europe and North America are also increasingly encountering patients with alpha-thalassemia due to increase in migration. Alpha-thalassemia is an inherited disease caused by mutations in a gene required for making a component of hemoglobin. Those mutations either prevent or reduce the production of hemoglobin, which can cause a shortage of mature red blood cells and lead to anemia. The mutations that cause alpha-thalassemia are more common in Asia, India, the Middle East and the Mediterranean where they are found in up to 20% of the population. But the increase in modern migration means that cases are now cropping up more often in other regions. Southern Mediterranean countries recognize the rise in patients with alpha-thalassemia and have increased resources to meet the growing demand appropriately, hence increasing the market for alpha thalassemia treatment globally.

By treatment type, the global market is segmented into blood transfusion, iron chelation, bone marrow transplant, gene therapy, and surgery. Blood transfusion is expected to be the largest market holder over the period of forecast (2020-2027).

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

North America is dominating the thalassemia treatment market in 2018 and estimated to hold the largest market size over the forecast period (2020-2027), owing to an increase in thalassemia incidences, highly aware population, advanced healthcare infrastructure and, favorable government initiatives. The cases of thalassemia disorder are increasing in the region due to an increase in migration. Thalassemia, once a rarity in the US, is increasingly encountered in clinical practice due to shifts in immigration. Thalassemia is becoming more prevalent in the US due to immigration of people from affected regions, with an approximately 7.5% increase over the last five decades. According to National Institute of Health, the overall prevalence of  Thalassemia is around 5.4% in US.

Thalassemia is a major public health concern in South Asia, and the situation is expected to deteriorate over the period of forecast (2020-2027); hence Asia Pacific is expected to grow at the highest CAGR over the period of forecast. Most information on thalassemia in South Asia comes from studies conducted in India. Due to extreme heterogeneity, an uneven frequency of thalassemia heterozygote or carrier in the range of 1% and 10% has been reported throughout different parts of India. However, the overall prevalence of thalassemia carriers has been estimated to be between 2.78% and 4% in India. This number translates to approximately 30–48 million beta-thalassemia carriers in India with a carrier rate of 5–7%. Many companies are launching their products in the market targeting the large population. Moreover, government and many other organizations are working in the region to create awareness among the population. Asian Network for Thalassemia Control is one such organization that focus on fact-finding regarding the extent of the problem in individual countries together with an account of the facilities that exist for the diagnosis and management of the different forms of thalassemia in each country. Guangxi, south China, where thalassemia is very common launched a prevention program in 2010.  They have set a “one-stop service unit” for thalassemia screening at Marriage Registration Centers (in China, all couples must be registered at these centers). This is where they educate newly married couples about birth control, HIV, and other issues including thalassemia, after which blood is drawn and sent to the hospital for a test.

Source: DataM Intelligence Analysis (2019)

Competitive Landscape

Some of the major key players in the market are Vifor Pharma, Kiadis Pharma, Gamida Cell, ApoPharma, bluebird bio, Inc., Novartis AG, Celgene Corporation, La Jolla Pharmaceutical, Sangamo Biosciences, and Acceleron Pharma.

In the thalassemia treatment market, bluebird bio Inc. is going to dominate the market, owning to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, which are contributing to the growth of the thalassemia treatment market globally.

In June 2019, bluebird bio, Inc. announced updated results from the completed Phase 1/2 Northstar (HGB-204) study, and new data from the Phase 3 Northstar-2 (HGB-207) and Phase 3 Northstar-3 (HGB-212) clinical studies of its LentiGlobin® gene therapy for patients with transfusion-dependent β-thalassemia, at the 24th European Hematology Association Congress in Amsterdam, the Netherlands.

In June 2019, Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.

In January 2019, Vifor Pharma is pleased to report positive phase-I trial results for its oral ferroportin inhibitor. Trial subjects received single oral doses of VIT-2763 (ferroportin inhibitor) for the treatment of beta-thalassemia.

Why Purchase the Report?

  • Visualize the composition of the thalassemia treatment market across each indication, in terms of type and by type highlighting the key commercial assets and players.

  • Identify commercial opportunities in thalassemia treatment by analyzing trends and co-development deals.

  • Excel data sheets with thousands of data points of thalassemia treatment market-level 4/5 segmentation.

  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Product mapping in excel for the key products of all major market players.

 

The Global Thalassemia Treatment Market report would provide an access to an approx., 53 market data table, 43 figures, and 190 pages.

 

Target Audience

 

Table of Content

  1. Thalassemia Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Thalassemia Market – Market Definition and Overview

  3. Thalassemia Market – Executive Summary

    1.  Market Snippet by Disease Type
    2. Market Snippet by Treatment Type
    3. Market Snippet by Region
    4. DataM CLO Scenario
  4. Thalassemia Market-Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. Rising prevalence of thalassemia
        2. A surge in investment in research and development
        3. Rise in public awareness
      2. Restraints
        1. Side effects caused by drugs
      3. Opportunity
      4. Impact Analysis
  5. Thalassemia Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Supply Chain Analysis
    3. Regulatory Analysis
    4. Epidemiology
  6. Thalassemia Market – By Disease Type

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    3. Market Attractiveness Index, By Disease Type
    4.  Alpha Thalassemia
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    5.  Beta Thalassemia
  7. Thalassemia Market – By Treatment Type

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    3.  Market Attractiveness Index, By Treatment Type
    4. Blood Transfusion
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
    5.  Iron Chelation Therapy
    6. Bone Marrow Transplant
    7. Gene Therapy
    8. Surgery
  8. Thalassemia Market – By Region

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    3. Market Attractiveness Index, By Region
    4. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    5. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    6. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    7. Asia-Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    8. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  9. Market – Competitive Landscape

    1. Competitive Scenario
    2. Competitor Thalassemia Strategy Analysis
    3. Comparative Product Portfolio Analysis
    4. Market Positioning/Share Analysis
    5. Mergers and Acquisitions Analysis
  10. Company Profiles

    1. Vifor Pharma *
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Kiadis Pharma
    3. Gamida Cell
    4. ApoPharma
    5. Bluebird Bio
    6. Novartis
    7. Celgene Corporation
    8. La Jolla Pharmaceutical
    9. Sangamo Bioscience
    10. Acceleron Pharma, Inc.( "List not exhaustive")
  11. Thalassemia Market – Premium Insights

  12. Thalassemia Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

List of Tables

Table 1 Global Thalassemia Market Value, By Disease Type, 2018,2022 & 2027 ($ Million)

Table 2 Global Thalassemia Market Value, By Treatment Type, 2018,2022 & 2027 ($ Million)

Table 3 Global Thalassemia Market Value, By Region, 2018,2022 & 2027 ($ Million)

Table 4 Global Thalassemia Market Value, By Disease Type, 2018,2022 & 2027 ($ Million)

Table 5 Global Thalassemia Market Value, By Disease Type, 2017-2027 ($ Million)

Table 6 Global Thalassemia Market Value, By Treatment Type, 2018,2022 & 2027 ($ Million)

Table 7 Global Thalassemia Market Value, By Treatment Type, 2017-2027 ($ Million)

Table 8 Global Thalassemia Market Value, By Region, 2018,2022 & 2027 ($ Million)

Table 9 Global Thalassemia Market Value, By Region, 2017-2027 ($ Million)

Table 10 North America Thalassemia Market Value, By Disease Type, 2017-2027 ($ Million)

Table 11 North America Thalassemia Market Value, By Treatment Type, 2017-2027 ($ Million)

Table 12 North America Thalassemia Market Value, By Country, 2017-2027 ($ Million)

Table 13 South America Thalassemia Market Value, By Disease Type, 2017-2027 ($ Million)

Table 14 South America Thalassemia Market Value, By Treatment Type, 2017-2027 ($ Million)

Table 15 South America Thalassemia Market Value, By Country, 2017-2027 ($ Million)

Table 16 Europe Thalassemia Market Value, By Disease Type, 2017-2027 ($ Million)

Table 17 Europe Thalassemia Market Value, By Treatment Type, 2017-2027 ($ Million)

Table 18 Europe Thalassemia Market Value, By Country, 2017-2027 ($ Million)

Table 19 Asia-Pacific Thalassemia Market Value, By Disease Type, 2017-2027 ($ Million)

Table 20 Asia-Pacific Thalassemia Market Value, By Treatment Type, 2017-2027 ($ Million)

Table 21 Asia-Pacific Thalassemia Market Value, By Country, 2017-2027 ($ Million)

Table 22 Middle East & Africa Thalassemia Market Value, By Disease Type, 2017-2027 ($ Million)

Table 23 Middle East & Africa Thalassemia Market Value, By Treatment Type, 2017-2027 ($ Million)

Table 24 Vifor Pharma: Overview

Table 25 Vifor Pharma: Product Portfolio

Table 26 Vifor Pharma: Key Developments

Table 27 Kiadis Pharma: Overview

Table 28 Kiadis Pharma: Product Portfolio

Table 29 Kiadis Pharma: Key Developments

Table 30 Gamida Cell: Overview

Table 31 Gamida Cell: Product Portfolio

Table 32 Gamida Cell: Key Developments

Table 33 ApoPharma: Overview

Table 34 ApoPharma: Product Portfolio

Table 35 ApoPharma: Key Developments

Table 36 Bluebird Bio: Overview

Table 37 Bluebird Bio: Product Portfolio

Table 38 Bluebird Bio: Key Developments

Table 39 Novartis: Overview

Table 40 Novartis: Product Portfolio

Table 41 Novartis: Key Developments

Table 42 Celgene Corporation: Overview

Table 43 Celgene Corporation: Product Portfolio

Table 44 Celgene Corporation: Key Developments

Table 45 La Jolla Pharmaceutical: Overview

Table 46 La Jolla Pharmaceutical: Product Portfolio

Table 47 La Jolla Pharmaceutical: Key Developments

Table 48 Sangamo Bioscience: Overview

Table 49 Sangamo Bioscience: Product Portfolio

Table 50 Sangamo Bioscience: Key Developments

Table 51 Acceleron Pharma, Inc.: Overview

Table 52 Acceleron Pharma, Inc.: Product Portfolio

Table 53 Acceleron Pharma, Inc.: Key Developments

 

List of Figures

Figure 1 Global Thalassemia Market Share, By Disease Type, 2018 & 2027 (%)

Figure 2 Global Thalassemia Market Share, By Treatment Type, 2018 & 2027 (%)

Figure 3 Global Thalassemia Market Share, By Region, 2018 & 2027 (%)

Figure 4 Global Thalassemia Market Value, 2017-2027 ($ Million)

Figure 5 Global Thalassemia Market Y-o-Y Growth, By Disease Type, 2018-2027 (%)

Figure 6 Alpha Thalassemia: Global Thalassemia Market Value, 2017-2027 ($ Million)

Figure 7 Beta Thalassemia: Global Thalassemia Market Value, 2017-2027 ($ Million)

Figure 8 Global Thalassemia Market Y-o-Y Growth, By Treatment Type, 2018-2027 (%)

Figure 9 Blood Transfusion: Global Thalassemia Market Value, 2017-2027 ($ Million)

Figure 10 Iron Chelation Therapy: Global Thalassemia Market Value, 2017-2027 ($ Million)

Figure 11 Bone Marrow Transplant: Global Thalassemia Market Value, 2017-2027 ($ Million)

Figure 12 Gene Therapy: Global Thalassemia Market Value, 2017-2027 ($ Million)

Figure 13 Surgery: Global Thalassemia Market Value, 2017-2027 ($ Million)

Figure 14 Global Thalassemia Market Y-o-Y Growth, By Region, 2018-2027 (%)

Figure 15 North America Thalassemia Market Value, 2017-2027 ($ Million)

Figure 16 North America Thalassemia Market Share, By Disease Type, 2018 & 2027 (%)

Figure 17 North America Thalassemia Market Share, By Treatment Type, 2018 & 2027 (%)

Figure 18 North America Thalassemia Market Share, By Country, 2018 & 2027 (%)

Figure 19 South America Thalassemia Market Value, 2017-2027 ($ Million)

Figure 20 South America Thalassemia Market Share, By Disease Type, 2018 & 2027 (%)

Figure 21 South America Thalassemia Market Share, By Treatment Type, 2018 & 2027 (%)

Figure 22 South America Thalassemia Market Share, By Country, 2018 & 2027 (%)

Figure 23 Europe Thalassemia Market Value, 2017-2027 ($ Million)

Figure 24 Europe Thalassemia Market Share, By Disease Type, 2018 & 2027 (%)

Figure 25 Europe Thalassemia Market Share, By Treatment Type, 2018 & 2027 (%)

Figure 26 Europe Thalassemia Market Share, By Country, 2018 & 2027 (%)

Figure 27 Asia-Pacific Thalassemia Market Value, 2017-2027 ($ Million)

Figure 28 Asia-Pacific Thalassemia Market Share, By Disease Type, 2018 & 2027 (%)

Figure 29 Asia-Pacific Thalassemia Market Share, By Treatment Type, 2018 & 2027 (%)

Figure 30 Asia-Pacific Thalassemia Market Share, By Country, 2018 & 2027 (%)

Figure 31 Middle East & Africa Thalassemia Market Value, 2017-2027 ($ Million)

Figure 32 Middle East & Africa Thalassemia Market Share, By Disease Type, 2018 & 2027 (%)

Figure 33 Middle East & Africa Thalassemia Market Share, By Treatment Type, 2018 & 2027 (%)

Figure 34 Vifor Pharma: Financials

Figure 35 Kiadis Pharma: Financials

Figure 36 Gamida Cell: Financials

Figure 37 ApoPharma: Financials

Figure 38 Bluebird Bio: Financials

Figure 39 Novartis: Financials

Figure 40 Celgene Corporation: Financials

Figure 41 La Jolla Pharmaceutical: Financials

Figure 42 Sangamo Bioscience: Financials

Figure 43 Acceleron Pharma, Inc.: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!

linkedinpinterest